linjc16/ctgov huggingface dataset:
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in China. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of insulin detemir or NPH-insulin given once daily at bedtime as add-on to oral anti-diabetic drug(s).

Official Title
-----------------
Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: insulin NPH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes HbA1C greater than 7.5% and less than or equal to 11.0% Currently on any oral antidiabetic drug (OAD) more than or equal to 3 months Exclusion Criteria: Previous acute treatment with insulin for more than 7 days. Treatment with OAD(s) which does not adhere to the approval labeling. Proliferate retinopathy or maculopathy that has required acute treatment within the last year. Known hypoglycaemia unawareness or recurrent major hypoglycaemia, that may interfere with study participation as judged by the Investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: insulin detemir|nan|
|Drug: insulin NPH|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | after 20 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FBG |  | after 20 weeks of treatment | 
| Safety profile |  | during 20 weeks treatment | 
| Proportion of subjects achieving HbA1c less than or equal to 7.0% |  | after 20 weeks of treatment | 
| Within-subject variation of self measured blood glucose (SMBG) before breakfast during the trial at the end of the trial |  | before breakfast during the trial at the end of the trial |
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant

Study Overview
=================
Brief Summary
-----------------
The Staphylococcus aureus is an important pathogen bacteria actuating as an agent of a wide variety of infections, such as the superficials to the disseminates ones, its commonly find into hospitals ambient, assailing mainly immunosupress patients. Around 30% to 50% of people carries this agent in their nasal bone as part of their normal flora, occuring larger in hospitals workers. The S. aureus is also known for its high capacity of developing resistance to various antibiotic. Facing these considerations, the importance of nursing precaution and the infections control inside hospitals ambient, the purpose of this present study aimed to verify the rates of carriers of S. aureus in nursing students and the connection with the hospitals time involvement during graduation in the Faculty de Medicine de Botucatu - UNESP, embracing the 4 years of graduation college.

Conditions
-----------------
Staphylococcal Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Students nursing Exclusion Criteria: Students nursing with infection

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Staphylococcus aureus carriers students nursing
Body PSOriasis: Long-term Relapse CONTROL

Study Overview
=================
Brief Summary
-----------------
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.

Official Title
-----------------
Body PSOriasis: Long-term Relapse Control in Patients With Psoriasis Vulgaris in Daily Clinical Practice of Russian Dermatologists.

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Drug: Any topical drug treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients planned to receive topical treatment of any kind to prevent relapse of symptoms Written informed consent Exclusion Criteria: Contraindications to selected treatment Ongoing systemic treatment of psoriasis with steroids, anti-inflammatory drugs or phototherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time of relapse | Length of relapse free period after start of maintenance strategy | Up to 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dermatology Life Quality Index | Standard QoL measure within dermatology | Up to 52 weeks | 
| PGA (physician's global assessment of symptoms) | 5-point verbal rating scale | Up to 52 weeks | 
| PsGA (patient's global assessment of symptoms) | 5-point verbal rating scale | Up to 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Topicals, Long-term
Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Betatrophin is a newly identified hormone that promotes pancreatic beta cell proliferation, improves glucose tolerance and regulates lipids metabolism. A recent study showed that circulating concentrations of betatrophin doubled in type 1 diabetes. The objective of this study is to investigate the association of serum betatrophin levels with the progression of diabetic retinopathy in patients with type 2 diabetes and the level of betatrophin in gestational diabetes patients and pregnant women.

Detailed Description
-----------------
200 subjects were recruited in this study and divided into six groups for comparison of the serum betatrophin. 70 healthy subjects and 20 healthy young volunteers were enrolled for investigating the role of betatrophin in energy homeostasis and the circadian rhythm. 50 patients with type 2 diabetes were classified into three groups by the stage of diabetic retinopathy. Rank test was used to analyze the correlation between the progression of diabetic retinopathy and circulating betatrophin. Betatrophin were measured by a commercially available enzyme-linked immunosorbent assay and confirmed via Western Blot.

Official Title
-----------------
Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects

Conditions
-----------------
Pregnancy, Gestational Diabetes Mellitus (GDM), Type 2 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus patients Patients with HbA1c >or= 7.0% Exclusion Criteria: Participation in other investigational Clinical Trial Type 1 diabetes mellitus patients Patients with history of severe hepatic dysfunction Treatment with antifungal agent especially Miconazole Patients with active smoking or history of smoking cessation less than 2 months

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Controls<br>Healthy subjects as control group. | |
| Type 2 diabetes<br>Patients with type 2 diabetes. | |
| Gestational diabetes mellitus<br>Patients with gestational diabetes mellitus. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum levels of betatrophin in type 2 diabetes patients, gestational diabetes patients and pregnant women |  | Up to one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of betatrophin concentration with other variables |  | Up to one month |
Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

Study Overview
=================
Brief Summary
-----------------
Port wine stain Birthmark is a congenital, progressive vascular malformation of human skin. However, even though the pulsed dye laser is considered as the treatment of choice for Port wine stain Birthmark the degree of fading can remain variable and unpredictable after laser treatment.

Detailed Description
-----------------
The researcher want to use the combination of radiofrequency electrical energy with pulsed dye laser light energy which can improve therapeutic outcome of Port wine stain Birthmark. This investigational device is essentially a combination of two commercially available systems cleared for marketing (K044351 and K052324) provided by Candela Laser Corporation.

Official Title
-----------------
Combined Bipolar Radiofrequency and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks

Conditions
-----------------
Port-Wine Stain

Intervention / Treatment
-----------------
* Device: Pulsed Dye Laser
* Device: Combined Bipolar Radiofrequency&Pulsed Dye Laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Port Wine Stain suitable for comparison testing Age > 12 years of age; minor will be accompanied in the room by parents or guardians during laser treatment Apparent good health as documented by medical history Ability to understand and carry out subject instructions Exclusion Criteria: History of photodermatoses or skin cancer Any therapy within the previous two months to the proposed port wine stain treatment sites Current participation in any other investigational drug or device evaluation Concurrent use of known photosensitizing drugs Inability to understand and carry out instructions

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pulsed Dye Laser<br>port wine stain treatment using Pulse Dye Laser | Device: Pulsed Dye Laser<br>* port wine stain<br>* Other names: candela-Laser;|
| Experimental: Bipolar Radiofrequency&Pulsed Dye Laser<br>Port wine stain using Combined Bipolar Radiofrequency&Pulsed Dye Laser | Device: Combined Bipolar Radiofrequency&Pulsed Dye Laser<br>* Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change in Blanching of Port Wine Stain | Port Wine Stain blood volume fractions in the skin before (fB1), and 8 weeks after (fB2) treatment will be determined using the corresponding visual reflectance spectra measured at the treatment sites. The primary outcome, degree of blanching, B, is computed as B = (fB1-fB2)/fB1. | 8 weeks |
Impact of Mobile Text Messaging on Follow Up Rates After Discharge From the Pediatric Emergency Department

Study Overview
=================
Brief Summary
-----------------
To compare the effectiveness of text message versus voice call as a method of contact for providing results of diagnostic tests and assuring ongoing care from the pediatric emergency department.

Detailed Description
-----------------
The investigators plan to conduct a prospective randomized controlled trial to compare two means of contacting patients and their caregivers after discharge from the emergency department in order to provide results of tests: text messaging (intervention group) vs. telephone call (standard group).

Official Title
-----------------
Impact of Mobile Text Messaging on Follow Up Rates After Discharge From the Pediatric Emergency Department

Conditions
-----------------
Duty to Recontact

Intervention / Treatment
-----------------
* Other: Text Message


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients under the age of 18 who have had diagnostic testing without finalized results prior to discharge from the emergency department Exclusion Criteria: Admitted patients Patients transferred to another facility Patients with critical values as results Do not have devices that can receive phone and text messages Cannot read English or Spanish

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Phone Call<br>Follow up contact is attempted via phone call. | |
| Experimental: Text Message<br>Follow up contact is attempted via text message. | Other: Text Message<br>* Patient contact attempted with text message.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of phone call or text message attempts to successful contact with study participant | A study practitioner will make one attempt per business day to contact the patient or caregiver to provide test results and arrange follow-up care; the method will be determined by the study arm to which the participant is assigned. Participants in the standard practice control arm will receive a telephone call. If a call is not answered, a voice message will be left instructing the patient/parent to call the Pediatric Follow-Up Office. Participants in the intervention arm will receive a text message using the same script. A successful contact will be recorded when a practitioner speaks directly to the patient or parent/guardian via phone. | Within 2 weeks. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Follow Up, Text Messaging
MRI Findings in Throwing Shoulders of Waterpolo Players

Study Overview
=================
Brief Summary
-----------------
MRI examination of 60 shoulders of waterpolo players (30 throwing shoulders as well as the opposite side) and 15 healthy probands as control group (30 shoulders of non waterpolo players. The correlation of MRI alteration and clinical symptomatic findings in both groups will be investigated. The clinical examination is performed by 2 board certified orthopedic surgeons and based on the Constant Murley Score.

Official Title
-----------------
MRI Findings in Throwing Shoulders of Waterpolo Players Abnormalities in Professional Waterpolo Players

Conditions
-----------------
Waterpolo Players, Non Throwing Shoulders

Intervention / Treatment
-----------------
* Other: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study shoulders of elite waterpolo players Study shoulders of healthy non throwing persons Age between 18-35 years Male Given informed consent Exclusion Criteria: Previous shoulder surgery Goal keeper Metallic implants Pacemaker Tattoos with metallic colors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: waterpolo players<br>30 throwing shoulders of waterpolo players | Other: MRI<br>* MRI and clinical investigation<br>|
| Other: controle group<br>15 healthy patients (non waterpolo players); 30 shoulders | Other: MRI<br>* MRI and clinical investigation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between alterations of SSP-tendon in MRI and clinical symptoms |  | 1 day |
Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
This trial aims at collecting standardized data concerning the early neurological clinical recovery of patients, 3 months after endovascular treatment of an acute ischemic stroke. Although this outcome is a major issue of patients' prognosis, it is rarely collected at this stage of their follow-up.

Official Title
-----------------
Assessment of Patients' Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke

Conditions
-----------------
Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute ischemic stroke endovascular treatment Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| early neurological clinical recovery | modified RANKIN score | 3 months after endovascular treatment of an acute ischemic stroke |
Prospective Register on the Etiologies of Cardiogenic Shock and Their Prognosis at One Year.

Study Overview
=================
Brief Summary
-----------------
Cardiogenic shock (CC) is one of the major challenges of current cardiology. Despite the difficulty of establishing a strict and consensual definition, it is accepted that the CC clinically corresponds to persistent hypotension (systolic blood pressure 90 mmHg for at least 30 minutes or need for vasopressor support) associated with signs of visceral hypoperfusion (confusion, mottling, oliguria, hyperlactatemia), and hemodynamic with a lowered heart index ( 1.8 L/min/m2) despite appropriate or high filling pressures. This definition of the European Society of Cardiology (ESC) masks however the great variability of hemodynamic tables grouped under the term of CC and severity levels, also variable.However, it was suggested that the etiology of CC influenced both its hemodynamic profile and therefore its therapeutic management but also its prognosis in the medium and long term.

Detailed Description
-----------------
CC diagnosis remains difficult to carry on admission and is sometimes delayed. Therefore, we would like to compare hemodynamic data from patients with CC status to those admitted for acute heart failure (ICA) to determine if a hemodynamic variable at entry would facilitate the diagnosis of CC.

Official Title
-----------------
Prospective Register on the Etiologies of Cardiogenic Shock and Their Prognosis at One Year.

Conditions
-----------------
Cardiogenic Shock

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in Cardiac Shock : 90 mmHg hypotension or requiring inotropic or vasopressor support, owered cardiac output ( 1.8 L/min/m2) to trans-thoracic cardiac ultrasound with high or normal filling pressures peripheral hypoperfusion. patients admitted for acute heart failure (ICA) (Acute pulmonary edema chart or left congestive heart failure without CC sign and with ultrasound FEVG at entry 40%.) Exclusion Criteria: Pregnant or nursing women Age 18 years Person of full age under guardianship Staying in a health or social facility Person not covered by a social security scheme Person deprived of liberty Shocks from other etiologies Patient with initial cardiac arrest Patient with cardiogenic shock due to right ventricular dysfunction Patient with pulmonary embolism Patient with tamponade Refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of Cardiac Shock |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | one month | 
| mortality |  | one year |